Ingunn Narverud1, Jeanine Roeters van Lennep2, Jacob J Christensen1, Jorie Versmissen2, Jon Michael Gran3, Per Ole Iversen4, Pål Aukrust5, Bente Halvorsen6, Thor Ueland7, Stine M Ulven8, Leiv Ose1, Marit B Veierød9, Eric Sijbrands2, Kjetil Retterstøl1, Kirsten B Holven10. 1. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O Box 1046 Blindern, 0317, Oslo, Norway; Lipid Clinic, Oslo University Hospital Rikshospitalet, P.O Box 4950 Nydalen, 0424, Oslo, Norway. 2. Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. 3. Oslo Centre for Biostatics and Epidemiology, Institute of Basic Medical Science, University of Oslo, Norway. 4. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O Box 1046 Blindern, 0317, Oslo, Norway; Department of Haematology, Oslo University Hospital, P.O Box 4950 Nydalen, 0424, Oslo, Norway. 5. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, P.O Box 4950 Nydalen, 0424, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, P.O Box 1171 Blindern, 0318, Oslo, Norway; Section of Clinical Immunology and Infectious Diseases, Oslo University Hospital Rikshospitalet, P.O Box 4950 Nydalen, 0424, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, P.O Box 1171 Blindern, 0318, Oslo, Norway; K.G. Jebsen TREC, The Faculty of Health Sciences, UiT- The Arctic University of Tromsø, 9037, Tromsø, Norway. 6. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, P.O Box 4950 Nydalen, 0424, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, P.O Box 1171 Blindern, 0318, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, P.O Box 1171 Blindern, 0318, Oslo, Norway. 7. Research Institute of Internal Medicine, Oslo University Hospital Rikshospitalet, P.O Box 4950 Nydalen, 0424, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, P.O Box 1171 Blindern, 0318, Oslo, Norway; K.G. Jebsen Inflammatory Research Center, P.O Box 1171 Blindern, 0318, Oslo, Norway; K.G. Jebsen TREC, The Faculty of Health Sciences, UiT- The Arctic University of Tromsø, 9037, Tromsø, Norway. 8. Department of Health, Nutrition and Management, Faculty of Health Sciences, Oslo and Akershus University College of Applied Sciences, P.O Box 4, St. Olavs Plass, 0130, Oslo, Norway. 9. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O Box 1046 Blindern, 0317, Oslo, Norway; Oslo Centre for Biostatics and Epidemiology, Institute of Basic Medical Science, University of Oslo, Norway. 10. Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, P.O Box 1046 Blindern, 0317, Oslo, Norway; Norwegian National Advisory Unit on Familial Hypercholesterolemia, Oslo University Hospital, Rikshospitalet, P.O Box 4950, Nydalen, Norway. Electronic address: kirsten.holven@medisin.uio.no.
Abstract
BACKGROUND AND AIMS: Pregnancy exerts metabolic changes with increasing levels of total cholesterol and triglycerides as prominent features. Maternal hypercholesterolemia may thus contribute to an unfavorable in utero environment potentially influencing the susceptibility of adult cardiovascular disease in the offspring. We investigated the impact of maternal familial hypercholesterolemia (FH) on pre-treatment plasma lipids and C-reactive protein (CRP) levels in non-statin treated FH children. METHODS: Children with FH (n = 1063) aged between 0 and 19 years were included. Of these, 500 had inherited FH maternally, 563 paternally and 97.6% had a verified FH mutation. Information about inheritance, mutation type and pretreatment levels of blood lipids and CRP was retrieved from the medical records. RESULTS: There were no significant differences in the plasma levels of lipids and C-reactive protein (CRP) in children with maternal FH compared with children with paternal FH, (0.12 ≤ P ≤ 0.90). Independent of which parent transmitted FH, children with LDL receptor negative mutations had significantly higher levels of total and LDL cholesterol and Apolipoprotein (Apo) B, and lower levels of HDL cholesterol and ApoA1, compared with children with other LDL receptor mutations (P < 0.001). CONCLUSION: Maternal inheritance of FH was not associated with detectable long-term effects in the offspring's phenotype measured by adverse lipid profiles and increased CRP levels, whereas a LDL receptor negative mutation was associated with an unfavorably phenotype in FH offspring. Our findings do not support the fetal origin of adulthood disease hypothesis, while at the same time not excluding the hypothesis since other pathways leading to atherosclerosis may be involved.
BACKGROUND AND AIMS: Pregnancy exerts metabolic changes with increasing levels of total cholesterol and triglycerides as prominent features. Maternal hypercholesterolemia may thus contribute to an unfavorable in utero environment potentially influencing the susceptibility of adult cardiovascular disease in the offspring. We investigated the impact of maternal familial hypercholesterolemia (FH) on pre-treatment plasma lipids and C-reactive protein (CRP) levels in non-statin treated FHchildren. METHODS:Children with FH (n = 1063) aged between 0 and 19 years were included. Of these, 500 had inherited FH maternally, 563 paternally and 97.6% had a verified FH mutation. Information about inheritance, mutation type and pretreatment levels of blood lipids and CRP was retrieved from the medical records. RESULTS: There were no significant differences in the plasma levels of lipids and C-reactive protein (CRP) in children with maternal FH compared with children with paternal FH, (0.12 ≤ P ≤ 0.90). Independent of which parent transmitted FH, children with LDL receptor negative mutations had significantly higher levels of total and LDL cholesterol and Apolipoprotein (Apo) B, and lower levels of HDL cholesterol and ApoA1, compared with children with other LDL receptor mutations (P < 0.001). CONCLUSION: Maternal inheritance of FH was not associated with detectable long-term effects in the offspring's phenotype measured by adverse lipid profiles and increased CRP levels, whereas a LDL receptor negative mutation was associated with an unfavorably phenotype in FH offspring. Our findings do not support the fetal origin of adulthood disease hypothesis, while at the same time not excluding the hypothesis since other pathways leading to atherosclerosis may be involved.
Authors: Jerad H Dumolt; Min Ma; Joyce Mathew; Mulchand S Patel; Todd C Rideout Journal: Am J Physiol Endocrinol Metab Date: 2019-08-27 Impact factor: 4.310
Authors: Michał Podgórski; Katarzyna Szatko; Małgorzata Stańczyk; Monika Pawlak-Bratkowska; Agnieszka Konopka; Ewa Starostecka; Marcin Tkaczyk; Sebastian Góreczny; Lena Rutkowska; Agnieszka Gach; Maciej Łukaszewski; Piotr Grzelak; Maciej Banach Journal: Lipids Health Dis Date: 2020-07-14 Impact factor: 3.876
Authors: Maria Mytilinaiou; Ioannis Kyrou; Mike Khan; Dimitris K Grammatopoulos; Harpal S Randeva Journal: Front Pharmacol Date: 2018-07-12 Impact factor: 5.810
Authors: Uma Ramaswami; Marta Futema; Martin P Bogsrud; Kirsten B Holven; Jeanine Roeters van Lennep; Albert Wiegman; Olivier S Descamps; Michal Vrablik; Tomas Freiberger; Hans Dieplinger; Susanne Greber-Platzer; Gabriele Hanauer-Mader; Mafalda Bourbon; Euridiki Drogari; Steve E Humphries Journal: Atherosclerosis Date: 2019-11-15 Impact factor: 5.162